+关注
闲鱼漂流
暂无个人介绍
IP属地：广西
9
关注
0
粉丝
0
主题
0
勋章
主贴
热门
闲鱼漂流
03-24
是2025年还是2015年？
联邦制药2025年收入132.106亿元 研发投入加码强化创新布局
去老虎APP查看更多动态
{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"4123813430743010","uuid":"4123813430743010","gmtCreate":1660710345613,"gmtModify":1660714628183,"name":"闲鱼漂流","pinyin":"xyplxianyupiaoliu","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/8a57998dc07eb0908ed35369ab4d5459","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":9,"tweetSize":1,"questionSize":0,"limitLevel":999,"accountStatus":3,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":1,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"228c86a078844d74991fff2b7ab2428d-1","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资经理虎","description":"证券账户累计交易金额达到10万美元","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.02.24","exceedPercentage":"60.95%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"wearingSort":0},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-2","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"资深虎友","description":"加入老虎社区1000天","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.05.16","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"wearingSort":0},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.04.08","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"wearingSort":0}],"userBadgeCount":3,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":3,"crmLevelSwitch":0,"location":"广西","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":546223312163144,"gmtCreate":1774364924813,"gmtModify":1774365824340,"author":{"id":"4123813430743010","authorId":"4123813430743010","name":"闲鱼漂流","avatar":"https://static.tigerbbs.com/8a57998dc07eb0908ed35369ab4d5459","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4123813430743010","idStr":"4123813430743010"},"themes":[],"title":"","htmlText":"是2025年还是2015年？","listText":"是2025年还是2015年？","text":"是2025年还是2015年？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/546223312163144","repostId":"1194548422","repostType":2,"repost":{"id":"1194548422","kind":"news","weMediaInfo":{"introduction":"港美股公告全覆盖","home_visible":1,"media_name":"公告速递","id":"1097772564","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"pubTimestamp":1774364689,"share":"https://www.laohu8.com/m/news/1194548422?lang=zh_CN&edition=full","pubTime":"2026-03-24 23:04","market":"hk","language":"zh","title":"联邦制药2025年收入132.106亿元 研发投入加码强化创新布局","url":"https://stock-news.laohu8.com/highlight/detail?id=1194548422","media":"公告速递","summary":"联邦制药于2015年度录得收入132.106亿元，同比下降4.0%；毛利为55.141亿元，较上年减少9.3%。未计利息、税项、折旧及摊销前溢利为32.472亿元，同比下降17.6%，除税前溢利25.27953亿元，同比下跌23.1%。本公司拥有人应占溢利为20.85902亿元，同比减少21.6%，每股基本盈利110.65分，同比下滑24.4%。董事会建议派发年度合计股息42分。财务管理方面，集团通过外部借贷与短期融资管控优化资金结构，年末现金及现金等价物余额106.0639亿元，流动负债维持在合理水平。","content":"<p>联邦制药（03933）于2025年度录得收入132.106亿元，同比下降4.0%；毛利为55.141亿元，较上年减少9.3%。未计利息、税项、折旧及摊销前溢利为32.472亿元，同比下降17.6%，除税前溢利25.27953亿元，同比下跌23.1%。本公司拥有人应占溢利为20.85902亿元，同比减少21.6%，每股基本盈利110.65分，同比下滑24.4%。董事会建议派发年度合计股息42分。</p><p>集团主营中间体、原料药及制剂产品，并在新型生物制药和创新药物研究方面积极布局。年内中间体及原料药业务销量及收入均受市场价格波动与需求调整影响而出现下滑；制剂产品实现销售收入69.978亿元，占总营收逾五成，主要包括胰岛素注射剂、抗菌素制剂及其他人用制剂，海外出口业务在维护原有市场的同时不断拓展新区域。</p><p>行业层面，医药政策鼓励创新及生物制药发展，市场对高端及差异化药物需求增加。集团持续加大研发投入，年内研发支出10.05亿元，涵盖糖尿病、肿瘤免疫、心血管等领域，并取得多项临床进展，包括用于治疗慢性肾脏病及肥胖适应症的UBT251注射液及GLP-1受体激动剂等项目。集团同时加强国际专利与注册申请布局，加快糖尿病、肥胖等重点治疗领域创新药物的商业化落地。</p><p>财务管理方面，集团通过外部借贷与短期融资管控优化资金结构，年末现金及现金等价物余额106.0639亿元，流动负债维持在合理水平。核心药品业务与延伸板块如大健康、动保及跨境电商等协同发展，新兴业务营收亦有增长。集团表示将持续推进差异化市场策略与研发体系升级，深化全球范围内的学术推广与多元化合作，以巩固竞争优势并拓展未来增长空间。</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>联邦制药2025年收入132.106亿元 研发投入加码强化创新布局</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n联邦制药2025年收入132.106亿元 研发投入加码强化创新布局\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1097772564\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">公告速递 </p>\n<p class=\"h-time\">2026-03-24 23:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>联邦制药（03933）于2025年度录得收入132.106亿元，同比下降4.0%；毛利为55.141亿元，较上年减少9.3%。未计利息、税项、折旧及摊销前溢利为32.472亿元，同比下降17.6%，除税前溢利25.27953亿元，同比下跌23.1%。本公司拥有人应占溢利为20.85902亿元，同比减少21.6%，每股基本盈利110.65分，同比下滑24.4%。董事会建议派发年度合计股息42分。</p><p>集团主营中间体、原料药及制剂产品，并在新型生物制药和创新药物研究方面积极布局。年内中间体及原料药业务销量及收入均受市场价格波动与需求调整影响而出现下滑；制剂产品实现销售收入69.978亿元，占总营收逾五成，主要包括胰岛素注射剂、抗菌素制剂及其他人用制剂，海外出口业务在维护原有市场的同时不断拓展新区域。</p><p>行业层面，医药政策鼓励创新及生物制药发展，市场对高端及差异化药物需求增加。集团持续加大研发投入，年内研发支出10.05亿元，涵盖糖尿病、肿瘤免疫、心血管等领域，并取得多项临床进展，包括用于治疗慢性肾脏病及肥胖适应症的UBT251注射液及GLP-1受体激动剂等项目。集团同时加强国际专利与注册申请布局，加快糖尿病、肥胖等重点治疗领域创新药物的商业化落地。</p><p>财务管理方面，集团通过外部借贷与短期融资管控优化资金结构，年末现金及现金等价物余额106.0639亿元，流动负债维持在合理水平。核心药品业务与延伸板块如大健康、动保及跨境电商等协同发展，新兴业务营收亦有增长。集团表示将持续推进差异化市场策略与研发体系升级，深化全球范围内的学术推广与多元化合作，以巩固竞争优势并拓展未来增长空间。</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"03933":"联邦制药"},"source_url":"","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1194548422","content_text":"联邦制药（03933）于2025年度录得收入132.106亿元，同比下降4.0%；毛利为55.141亿元，较上年减少9.3%。未计利息、税项、折旧及摊销前溢利为32.472亿元，同比下降17.6%，除税前溢利25.27953亿元，同比下跌23.1%。本公司拥有人应占溢利为20.85902亿元，同比减少21.6%，每股基本盈利110.65分，同比下滑24.4%。董事会建议派发年度合计股息42分。集团主营中间体、原料药及制剂产品，并在新型生物制药和创新药物研究方面积极布局。年内中间体及原料药业务销量及收入均受市场价格波动与需求调整影响而出现下滑；制剂产品实现销售收入69.978亿元，占总营收逾五成，主要包括胰岛素注射剂、抗菌素制剂及其他人用制剂，海外出口业务在维护原有市场的同时不断拓展新区域。行业层面，医药政策鼓励创新及生物制药发展，市场对高端及差异化药物需求增加。集团持续加大研发投入，年内研发支出10.05亿元，涵盖糖尿病、肿瘤免疫、心血管等领域，并取得多项临床进展，包括用于治疗慢性肾脏病及肥胖适应症的UBT251注射液及GLP-1受体激动剂等项目。集团同时加强国际专利与注册申请布局，加快糖尿病、肥胖等重点治疗领域创新药物的商业化落地。财务管理方面，集团通过外部借贷与短期融资管控优化资金结构，年末现金及现金等价物余额106.0639亿元，流动负债维持在合理水平。核心药品业务与延伸板块如大健康、动保及跨境电商等协同发展，新兴业务营收亦有增长。集团表示将持续推进差异化市场策略与研发体系升级，深化全球范围内的学术推广与多元化合作，以巩固竞争优势并拓展未来增长空间。","news_type":1,"symbols_score_info":{"03933":1}},"isVote":1,"tweetType":1,"viewCount":40,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":546223312163144,"gmtCreate":1774364924813,"gmtModify":1774365824340,"author":{"id":"4123813430743010","authorId":"4123813430743010","name":"闲鱼漂流","avatar":"https://static.tigerbbs.com/8a57998dc07eb0908ed35369ab4d5459","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4123813430743010","idStr":"4123813430743010"},"themes":[],"title":"","htmlText":"是2025年还是2015年？","listText":"是2025年还是2015年？","text":"是2025年还是2015年？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/546223312163144","repostId":"1194548422","repostType":2,"repost":{"id":"1194548422","kind":"news","weMediaInfo":{"introduction":"港美股公告全覆盖","home_visible":1,"media_name":"公告速递","id":"1097772564","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"pubTimestamp":1774364689,"share":"https://www.laohu8.com/m/news/1194548422?lang=zh_CN&edition=full","pubTime":"2026-03-24 23:04","market":"hk","language":"zh","title":"联邦制药2025年收入132.106亿元 研发投入加码强化创新布局","url":"https://stock-news.laohu8.com/highlight/detail?id=1194548422","media":"公告速递","summary":"联邦制药于2015年度录得收入132.106亿元，同比下降4.0%；毛利为55.141亿元，较上年减少9.3%。未计利息、税项、折旧及摊销前溢利为32.472亿元，同比下降17.6%，除税前溢利25.27953亿元，同比下跌23.1%。本公司拥有人应占溢利为20.85902亿元，同比减少21.6%，每股基本盈利110.65分，同比下滑24.4%。董事会建议派发年度合计股息42分。财务管理方面，集团通过外部借贷与短期融资管控优化资金结构，年末现金及现金等价物余额106.0639亿元，流动负债维持在合理水平。","content":"<p>联邦制药（03933）于2025年度录得收入132.106亿元，同比下降4.0%；毛利为55.141亿元，较上年减少9.3%。未计利息、税项、折旧及摊销前溢利为32.472亿元，同比下降17.6%，除税前溢利25.27953亿元，同比下跌23.1%。本公司拥有人应占溢利为20.85902亿元，同比减少21.6%，每股基本盈利110.65分，同比下滑24.4%。董事会建议派发年度合计股息42分。</p><p>集团主营中间体、原料药及制剂产品，并在新型生物制药和创新药物研究方面积极布局。年内中间体及原料药业务销量及收入均受市场价格波动与需求调整影响而出现下滑；制剂产品实现销售收入69.978亿元，占总营收逾五成，主要包括胰岛素注射剂、抗菌素制剂及其他人用制剂，海外出口业务在维护原有市场的同时不断拓展新区域。</p><p>行业层面，医药政策鼓励创新及生物制药发展，市场对高端及差异化药物需求增加。集团持续加大研发投入，年内研发支出10.05亿元，涵盖糖尿病、肿瘤免疫、心血管等领域，并取得多项临床进展，包括用于治疗慢性肾脏病及肥胖适应症的UBT251注射液及GLP-1受体激动剂等项目。集团同时加强国际专利与注册申请布局，加快糖尿病、肥胖等重点治疗领域创新药物的商业化落地。</p><p>财务管理方面，集团通过外部借贷与短期融资管控优化资金结构，年末现金及现金等价物余额106.0639亿元，流动负债维持在合理水平。核心药品业务与延伸板块如大健康、动保及跨境电商等协同发展，新兴业务营收亦有增长。集团表示将持续推进差异化市场策略与研发体系升级，深化全球范围内的学术推广与多元化合作，以巩固竞争优势并拓展未来增长空间。</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>联邦制药2025年收入132.106亿元 研发投入加码强化创新布局</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n联邦制药2025年收入132.106亿元 研发投入加码强化创新布局\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1097772564\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">公告速递 </p>\n<p class=\"h-time\">2026-03-24 23:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>联邦制药（03933）于2025年度录得收入132.106亿元，同比下降4.0%；毛利为55.141亿元，较上年减少9.3%。未计利息、税项、折旧及摊销前溢利为32.472亿元，同比下降17.6%，除税前溢利25.27953亿元，同比下跌23.1%。本公司拥有人应占溢利为20.85902亿元，同比减少21.6%，每股基本盈利110.65分，同比下滑24.4%。董事会建议派发年度合计股息42分。</p><p>集团主营中间体、原料药及制剂产品，并在新型生物制药和创新药物研究方面积极布局。年内中间体及原料药业务销量及收入均受市场价格波动与需求调整影响而出现下滑；制剂产品实现销售收入69.978亿元，占总营收逾五成，主要包括胰岛素注射剂、抗菌素制剂及其他人用制剂，海外出口业务在维护原有市场的同时不断拓展新区域。</p><p>行业层面，医药政策鼓励创新及生物制药发展，市场对高端及差异化药物需求增加。集团持续加大研发投入，年内研发支出10.05亿元，涵盖糖尿病、肿瘤免疫、心血管等领域，并取得多项临床进展，包括用于治疗慢性肾脏病及肥胖适应症的UBT251注射液及GLP-1受体激动剂等项目。集团同时加强国际专利与注册申请布局，加快糖尿病、肥胖等重点治疗领域创新药物的商业化落地。</p><p>财务管理方面，集团通过外部借贷与短期融资管控优化资金结构，年末现金及现金等价物余额106.0639亿元，流动负债维持在合理水平。核心药品业务与延伸板块如大健康、动保及跨境电商等协同发展，新兴业务营收亦有增长。集团表示将持续推进差异化市场策略与研发体系升级，深化全球范围内的学术推广与多元化合作，以巩固竞争优势并拓展未来增长空间。</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"03933":"联邦制药"},"source_url":"","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1194548422","content_text":"联邦制药（03933）于2025年度录得收入132.106亿元，同比下降4.0%；毛利为55.141亿元，较上年减少9.3%。未计利息、税项、折旧及摊销前溢利为32.472亿元，同比下降17.6%，除税前溢利25.27953亿元，同比下跌23.1%。本公司拥有人应占溢利为20.85902亿元，同比减少21.6%，每股基本盈利110.65分，同比下滑24.4%。董事会建议派发年度合计股息42分。集团主营中间体、原料药及制剂产品，并在新型生物制药和创新药物研究方面积极布局。年内中间体及原料药业务销量及收入均受市场价格波动与需求调整影响而出现下滑；制剂产品实现销售收入69.978亿元，占总营收逾五成，主要包括胰岛素注射剂、抗菌素制剂及其他人用制剂，海外出口业务在维护原有市场的同时不断拓展新区域。行业层面，医药政策鼓励创新及生物制药发展，市场对高端及差异化药物需求增加。集团持续加大研发投入，年内研发支出10.05亿元，涵盖糖尿病、肿瘤免疫、心血管等领域，并取得多项临床进展，包括用于治疗慢性肾脏病及肥胖适应症的UBT251注射液及GLP-1受体激动剂等项目。集团同时加强国际专利与注册申请布局，加快糖尿病、肥胖等重点治疗领域创新药物的商业化落地。财务管理方面，集团通过外部借贷与短期融资管控优化资金结构，年末现金及现金等价物余额106.0639亿元，流动负债维持在合理水平。核心药品业务与延伸板块如大健康、动保及跨境电商等协同发展，新兴业务营收亦有增长。集团表示将持续推进差异化市场策略与研发体系升级，深化全球范围内的学术推广与多元化合作，以巩固竞争优势并拓展未来增长空间。","news_type":1,"symbols_score_info":{"03933":1}},"isVote":1,"tweetType":1,"viewCount":40,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}
